NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
Clinical Trials
15 trialsNCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT04763083 2023-07-07
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Phase 1 Unknown
NCT05487651 2023-05-18
ANCHOR2
Athenex, Inc.
Phase 1 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04648475 2023-04-18
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04649983 2023-04-18
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05619861 2022-11-17
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT01976520 2021-04-08
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
XEME Biopharma Inc.
Phase 1 Unknown
NCT04439721 2021-01-06
γδT
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04156243 2019-11-12
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT03383952 2017-12-27
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
Immune Cell, Inc.
Phase 1 Unknown
NCT02963038 2017-04-28
CAR T Cells for Refractory B Cell Malignancy
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Unknown
NCT02672501 2016-02-03
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown